Oric Pharmaceuticals Stock Quote ORIC - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

7.64

Bid

7.65

Ask

7.69

Volume

180,934

7.62 Day's Range 7.99

4.89 52 Week Range 16.65

Market Cap

517.447M

Previous Close

8.08

Open

7.99

Last Trade

7.6306

Last Trade Time

12:25:20

Financial Volume

$ 1,405,113

VWAP

7.7659

Average Volume (3m)

573,445

Shares Outstanding

67,375,847

Dividend Yield

PE Ratio

-5.14

Earnings Per Share (EPS)

-1.49

Revenue

Net Profit

-100.7M

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.oricpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was $8.08. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of $ 4.89 to $ 16.65.

Oric Pharmaceuticals currently has 67,375,847 shares outstanding. The market capitalization of Oric Pharmaceuticals is $517.45 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.14.

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an...

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-2.34	-23.4468937876	9.98	10.03	7.62	443662	8.96952555	CS
4	-5.88	-43.4911242604	13.52	14.07	7.62	492576	10.57459077	CS
12	-3.44	-31.0469314079	11.08	16.65	7.62	573445	12.62997095	CS
26	1.58	26.0726072607	6.06	16.65	5.79	491391	10.69203951	CS
52	2.28	42.5373134328	5.36	16.65	4.89	439529	9.05667197	CS
156	-15.48	-66.955017301	23.12	26.7	2.36	389677	8.43833335	CS
260	-18.36	-70.6153846154	26	40.81	2.36	350079	12.01648577	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ACONAclarion Inc	$ 0.4917 (70.73%)	90.35M
SGBXSafe and Green Holdings Corporation	$ 0.2321 (61.07%)	104.08M
YYGHYY Group Holding Ltd	$ 3.5605 (57.54%)	15.03M
BRFHBarfresh Food Group Inc	$ 1.46 (41.75%)	35.52M
PCSAProcessa Pharmaceuticals Inc	$ 2.264 (39.75%)	53.41M
EJHE Home Household Service Holdings Ltd	$ 0.7635 (-73.76%)	9.8M
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.2741 (-35.55%)	13.03M
ATNIATN International Inc	$ 19.34 (-32.66%)	191.71k
BNAIBrand Engagement Network Inc	$ 2.61 (-30.03%)	165.17k
CYCCCyclacel Pharmaceuticals Inc	$ 1.61 (-30.00%)	2.98M
SGBXSafe and Green Holdings Corporation	$ 0.2321 (61.07%)	108.48M
SQQQProShares UltraPro Short QQQ	$ 12.23 (3.56%)	92.63M
ACONAclarion Inc	$ 0.4917 (70.73%)	90.51M
TSLATesla Inc	$ 163.6375 (0.93%)	66.37M
PCSAProcessa Pharmaceuticals Inc	$ 2.264 (39.75%)	61.03M